Help appealing denials for this first BTK inhibitor for chronic ITP.

Appeal Your Wayrilz Denial

Get access to this first oral BTK inhibitor for immune thrombocytopenia.

Understanding Your Wayrilz (rilzabrutinib) Denial

Wayrilz (rilzabrutinib) is the first BTK inhibitor approved for adults with persistent or chronic immune thrombocytopenia (ITP) who have had insufficient response to previous treatment. ITP causes dangerously low platelet counts and bleeding risk. If standard treatments haven't worked, you deserve access to this targeted therapy.

Common Reasons for Denial

! Prior authorization required
! Must try steroids first
! Must try other ITP therapies (IVIG, TPO-RA) first
! Step therapy requirement not met
! Platelet count documentation inadequate
! Specialty tier drug not covered

How We Help

We help you document your platelet count history, prior ITP treatments and their results, bleeding episodes, and why Wayrilz is the appropriate next step in your care.

Start your Wayrilz appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Rilzabrutinib is a reversible BTK inhibitor that reduces platelet destruction by inhibiting Fc receptor signaling in macrophages.

✓ Clinical trials demonstrated significant platelet count improvements in patients with persistent or chronic ITP who had failed prior treatments.

✓ ITP can cause life-threatening bleeding, particularly when platelet counts fall below 20,000/mcL.

✓ Oral targeted therapy offers convenience and tolerability advantages compared to infusion-based treatments.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Sanofi HemAssist (Wayrilz)

Eligible patients may pay as little as $0 copay. QuickStart program provides first month free while awaiting coverage. Patient Assistance Program for uninsured. Call 1-833-723-5463.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Organization for Rare Disorders (NORD)

Leading patient advocacy organization for rare disease community.

Global Genes

Leading rare disease patient advocacy organization connecting and empowering patients.

Frequently Asked Questions

Most insurers require you to have tried and failed or been intolerant to first-line therapies like steroids, IVIG, or TPO receptor agonists (romiplostim, eltrombopag). Document all prior treatments and why they failed.

Include your platelet count history over time, any bleeding episodes (bruising, nosebleeds, gum bleeding, heavy periods), transfusion requirements, and impact on daily activities.

Ready to Fight Your Wayrilz (rilzabrutinib) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Sanofi. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.